ACHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Acadia Healthcare (ACHC) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are some positive catalysts, the financial performance, technical indicators, and recent trading sentiment suggest caution. Holding the stock or waiting for a more favorable entry point would be prudent.
The MACD is positive and contracting, indicating a potential weakening of upward momentum. RSI is at 90.127, signaling the stock is overbought. Moving averages are converging, suggesting indecision in price direction. Key resistance levels are at $24.106 and $26.144, while support levels are at $20.807 and $17.509.
Analysts have raised price targets recently, with some maintaining Buy ratings.
The global market for mental health treatments is expected to grow significantly, which could benefit Acadia Healthcare in the long term.
The company has shown revenue growth of 6.10% YoY in the latest quarter.
Hedge funds are selling the stock, with a 194.77% increase in selling activity last quarter.
Canyon Capital Advisors exited its position, reflecting a pessimistic outlook.
The company reported a significant net income loss of $1.18 billion in Q4 2025, with EPS dropping by 3820% YoY.
The RSI indicates the stock is overbought, and technical indicators suggest caution.
In Q4 2025, revenue increased by 6.10% YoY to $821.46 million. However, net income dropped dramatically to -$1.18 billion, down 3710.36% YoY, and EPS fell to -$13.02, down 3820% YoY. Gross margin remained flat at 100%. The financials indicate operational and profitability challenges.
Recent analyst ratings are mixed. While some analysts raised price targets and maintained Buy ratings, others expressed concerns about operational pressures, Medicaid challenges, and limited near-term catalysts. The price targets range from $15 to $28, with a median target around $22-$24, close to the current price.
